Background: Comprehensive genomic profiling (CGP) identifies molecular alterations to support diagnosis and guide therapy in patients with cancer, yet real-world evidence on its clinical impact remains limited. We evaluated the clinical utility of equitable and population-based CGP implementation within a publicly funded healthcare system, aiming to identify actionable alterations and support treatment recommendations in patients with advanced cancer. Methods: IMPRESS-Norway is a nationwide precision medicine trial enrolling patients with treatment-refractory advanced malignancies across oncology centres. Tumour tissue was analysed using the TruSight Oncology 500 assay (TSO500, Illumina) at four regional laboratories within the Infrastructure for Precision Diagnostics (InPreD), a national programme for implementing advanced diagnostics. Results were reviewed by the national Molecular Tumour Board (MTB) to identify actionable alterations and provide biomarker-guided treatment recommendations. Findings: From April 2021 to August 2024, 1,964 patients referred for molecular profiling consented to IMPRESS-Norway, of whom 1,835 were analysed with TSO500 and evaluated by the MTB. Of these, 769 (42%) were identified with at least one actionable alteration, and 545 (30%) received a therapy recommendation through IMPRESS-Norway (24%), other clinical trials (3%), standard-of-care (2%), or off-label programmes (0·6%). The most common actionable alterations involved PIK3CA, BRAF, ERBB2, NRAS and high tumour mutational burden. Median turnaround time from requisition to MTB recommendation was 37 days (IQR 30-47). Interpretation: Nationwide implementation of CGP within a publicly funded healthcare system is feasible and supports equal access to molecular diagnostics, enabling targeted therapies and clinical trial enrolment for a substantial proportion of patients with advanced cancer. Ongoing collection of comprehensive, structured, and standardised real-world data provides evidence for clinical utility, supports translational research, and facilitates National evaluation of cost-effectiveness of CGP in routine practice.